Teva Pharmaceutical Industries has decided not to pursue development of laquinimod, and has returned rights to the drug back to Swedish group Active Biotech.
Teva Pharmaceutical Industries and partner Active Biotech say a late-stage trial of laquinimod has missed its primary endpoint, with the drug failing to halt the progression of multiple sclerosis in patients with relapsing remitting forms of the disease (RRMS).